Key facts
- This page summarizes Robert E. George's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Jun 2022, 19:03.
Robert E. George - 20 Jun 2022 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)
- Reporting relationship
- Director
- Issuer ticker
- MBRX
- Reported as of
- 20 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Jun 2022, 19:03:42 UTC
- Prior SEC filing
- 09 Jun 2021
- Next SEC filing
- 26 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Foster by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert E. George filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 22 Jun 2022.
Change
- Previous filing in this sequence was filed on 09 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBRX
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +23,333
- Change %
- +87%
- Price
- Shares after
- 50,001
- Date
- 20 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 23,333
- Exercise price
- $1.49
- Footnotes
- F1, F3
MBRX
transaction
Derivative
Stock option (right to buy)
Award
- Transaction value
- Shares
- +15,000
- Change %
- +30%
- Price
- Shares after
- 65,001
- Date
- 20 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $1.49
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The options set forth in this table vest in three equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.
Footnote F2
The options set forth in this table vest on the earlier of one year from the date of the Company's 2022 annual meeting of stockholders or on the date of the next annual meeting of stockholders, subject the grantee's continued service on the Company's Board of Directors on each vesting date.
Footnote F3
The options were issued in connection with the reporting person's Board of Director service to the Company.